Aggressive vestibular schwannomas showing postoperative rapid growth - Their association with decreased p27 expression

Journal of Neuro-Oncology

Volumn 75, Issue 2, 2005, Pages 203-207

  Seol, Ho Jun ^a   Jung, Hee Won ^b,e   Park, Sung Hye ^b   Hwang, Sung Kyun ^c   Kim, Dong Gyu ^b,e   Paek, Sun Ha ^b,e   Chung, Young Seob ^b,e   Lee, Chang Sub ^d  

^a Kangwon National University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d Jeju National University School of Medicine   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

Aggressive; p27; Vestibular schwannoma

Indexed keywords

CASPASE 3; FAS ANTIGEN; FAS LIGAND; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; GROWTH RATE; HUMAN; IMMUNOHISTOCHEMISTRY; NEURILEMOMA; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR RECURRENCE; VESTIBULAR SCHWANNOMA;

CELL PROLIFERATION; CHI-SQUARE DISTRIBUTION; CRANIAL NERVE NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KOREA; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; NEUROMA, ACOUSTIC; POSTOPERATIVE PERIOD; REOPERATION; RETROSPECTIVE STUDIES; TIME FACTORS; VESTIBULOCOCHLEAR NERVE DISEASES;

EID: 29244448652     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-2886-0     Document Type: Article

References (32)

1. Aguiar PH, Tatagiba M, Dankoweit-Timpe E, Matties C, Samii M, Ostertag H: Proliferative acitivity of acoustic neurilemomas without neurofibromatosis determined by monoclonal antibody MIB 1. Acta Neurochir (Wien) 134: 35-39, 1995
2. Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Holland FJ, Maher ER: A molecular, clinical, and immunological study of vestibular schwannoma. Otolaryngol Head Neck Surg 116: 426-430, 1997
3. Nedzelski JM, Canter RJ, Kassel EE, Rowed DW, Tator CH: Is no treatment good treatment in the management of acoustic neuromas in the elderly?. Laryngoscope 96: 825-829, 1986
4. Ogawa K, Kanzaki J, Ogawa S, Yamamoto M, Ikeda S, Shiobara R: The growth rate of acoustic neurinomas. Acta Otolaryngol (Stockh) [Suppl] 487: 157-163, 1991
5. Rosenberg SI: Natural history of acoustic neuromas. Laryngoscope 110: 497-508, 2000
6. Silverstein H, McDaniel A, Norrell H, Wazen J: Conservative management of acoustic neuroma in the elderly patient. Laryngoscope 95: 766-770, 1985
7. Wazen J, Silverstein H, Norrell H, Besse B: Preoperative and postoperative growth rates in acoustic neuromas documented with CT scanning. Otolaryngol Head Neck Surg 93: 151-155, 1985
8. Kameyama S, Tanaka R, Honda Y, Kawaguchi T, Honda Y, Yamazaki H, Hasegawa A: Long-term follow-up of residual intracanicular tumours after subtotal removal of acoustic neuromas. Acta Neurichir (Wien) 138: 206-209, 1996
9. Hwang SK, Kim DG, Paek SH, Kim CY, Kim MK, Chi JG, Jung HW: Aggressive vestibular schwannomas with postoperative rapid growth: clinicopathological analysis of 15 cases. Neurosurgery 51: 1381-1390, 2002
10. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85: 733-744, 1996
11. Ikeda H, Beauchamp RL, Yoshimoto T, Yandell DW: Detection of heterozygous mutation in the retinoblastoma gene in a human pituitary adenoma using PCR-SSCP analysis and direct sequencing. Endocr Pathol 6: 189-196, 1995
12. Ikeda H, Yoshimoto T, Shida N: Molecular analysis of p21 and p27 genes in human pituitary adenomas. Br J Cancer 76: 1119-1123, 1997
13. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA: Effects of an Rb mutation in the mouse. Nature 359: 295-300, 1992
14. Mawrin C, Kirches E, Dietzmann K, Roessner A, Boltze C: Expression pattern of apoptotic markers in vestibular schwannomas. Pathol Res Pract 198: 813-819, 2002
15. Lasak JM, Welling DB, Akhmametyeva EM, Salloum M, Chang LS: Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas. Laryngoscope 112: 1555-1561, 2002
16. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y: CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12: 2899-2911, 1998
17. Woloschak M, Yu A, Xiao J, Post KD: Frequent loss of the P16INK4a gene product in human pituitary tumors. Cancer Res 56: 2493-2496, 1996
18. Kamiya M, Nakazato Y: The expression of cell cycle regulatory proteins in oligodendroglial tumors. Clin Neuropathol 21: 52-65, 2002
19. Liu J, Estes ML, Drazba JA, Liu H, Prayson R, Kondo S, Jacobs BS, Barnett GH, Barna BP: Anti-sense oligonucleotide of p21(waf1/ cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells. Oncogene 19: 661-669, 2000
20. Wang ZM, Hu J, Zhou D, Xu ZY, Panasci LC, Chen ZP: Tri-chostatin A inhibits proliferation and induces expression of p21WAF and p27 in human brain tumor cell lines. Ai Zheng 21: 1100-1105, 2002
21. Craig C, Wersto R, Kim M, Ohri E, Li Z, Katayose D, Lee SJ, Trepel J, Cowan K, Seth P: A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 14: 2283-2289, 1997
22. Park KH, Seol JY, Yoo CG, Kim YW, Han SK, Lee EH, Kim CM, Shim YS, Lee CT: Adenovirus expressing p27(Kip1) induces growth arrest of lung cancer cell lines and suppresses the growth of established lung cancer xenografts. Lung Cancer 31: 149-155, 2001
23. Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B, Chang LS: cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 23: 736-748, 2002
24. Lloyd RV, Jin L, Qian X, Kulig E: Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 150: 401-407, 1997
25. Cordon-Cardo C: Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147: 545-560, 1995
26. Komatsubara K, Tahara S, Umeoka K, Sanno N, Teramoto A, Osamura RY: Immunohistochemical analysis of p27 (Kip1) in human pituitary glands and in various types of pituitary adenomas. Endocr Pathol 12: 181-188, 2001
27. Nagata S: Apoptosis by death factor. Cell 88: 355-365, 1997
28. Sheikh MS, Fornace AJ Jr: Death and decoy receptors and p53-mediated apoptosis. Leukemia 14: 1509-1513, 2000
29. Ye H, Wu H: Thermodynamic characterization of the interaction between TRAF2 and tumor necrosis factor receptor peptides by isothermal titration calorimetry. Proc Natl Acad Sci USA 97: 8961-8966, 2000
30. Park SH, Kim HK, Kim H, Ro JY: Apoptosis in thymic epithelial tumors. Pathol Res Pract 198: 461-467, 2002
31. Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-679, 1990
32. Louis DN, Deimling A, Chung RY, Rubio MP, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AD, Seizinger BR: Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52: 31-38, 1993